Article
Genomic and prognostic heterogeneity among RAS/BRAFV600E /TP53 co-mutated resectable colorectal liver metastases.
Molecular oncology - 1 Apr 2021
Berg Kaja C G, Brunsell Tuva H, Sveen Anita, Alagaratnam Sharmini, Bjørnslett Merete, Hektoen Merete, Brudvik Kristoffer W, Røsok Bård I, Bjørnbeth Bjørn Atle, Nesbakken Arild, Lothe Ragnhild A
Abstract excerpt
Hepatic resection is potentially curative for patients with colorectal liver metastases, but the treatment benefit varies. KRAS/NRAS (RAS)/TP53 co-mutations are associated with a poor prognosis after resection, but there is large variation in patient outcome within the mutation groups, and genetic testing is currently not used to evaluate benefit from surgery. We have investigated the potential for improved...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.